BiotechTube
Ancora Bio

Ancora Bio

Cambridge, United States· Est.
ancorabiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Ancora Biotech is a strategic holding entity formed by former executives and investors of Teneobio to advance a portfolio of three multi-specific antibody programs. Its most advanced asset, TNB-486 (anti-CD19xCD3), is in Phase 1 for B-cell malignancies, while two preclinical programs target CD38 for metabolic diseases and HBVxCD3 for a functional cure of chronic hepatitis B. The company's model involves spinning out assets into dedicated subsidiaries (TeneoTwo, TeneoFour, TeneoTen) while centralizing oversight of manufacturing and clinical development. Key financial backers include Lightspeed Venture Partners and Sutter Hill Ventures.

OncologyMetabolic DiseasesInfectious Diseases

Technology Platform

Legacy access to Teneobio's transgenic rat platform for discovering fully human, multi-specific antibodies (including T cell engagers and biparatopic antibodies) without an Fc region.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

Ancora has the opportunity to pioneer first-in-class therapies in large, underserved markets: a novel NAD+-boosting therapy for age-related metabolic diseases and a potentially curative T cell engager for chronic hepatitis B.
The successful AstraZeneca deal for TNB-486 validates the platform and provides capital to de-risk these earlier-stage, high-potential programs.

Risk Factors

The two lead programs are highly novel and preclinical, carrying significant biological and clinical development risk.
The company's future now depends entirely on these unproven assets following the exit of its most advanced program.
The spin-out model, while flexible, may create strategic complexity.

Competitive Landscape

TNB-486 entered a competitive B-cell malignancy space with multiple approved CD19-targeting therapies. TNB-738 faces no direct competitors but must prove a new disease mechanism. The anti-HBVxCD3 program would compete in a nascent but active field of companies pursuing curative HBV therapies, including other immunotherapies and siRNA approaches.

More companies in Biologics / Biosimilars →More companies in United States →